Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycin

British Journal of Cancer

Volumn 87, Issue 7, 2002, Pages 783-789

  Liu, D ^a   Hutchinson, O C ^a   Osman, S ^a   Price, P ^a   Workman, P ^b   Aboagye, Eric O ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Choline; ERK1 2; Geldanamycin; Pharmacodynamic; Phosphocholine

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; CHOLINE; CYCLIN DEPENDENT KINASE INHIBITOR; GELDANAMYCIN; HEMICHOLINIUM 3; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHORYLCHOLINE; ROSCOVITINE; SIGNAL TRANSDUCTION INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CELL GROWTH; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; ISOTOPE LABELING; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

BENZOQUINONES; BLOTTING, WESTERN; CARBON RADIOISOTOPES; CELL DIVISION; CELL SURVIVAL; CHOLINE; HUMANS; LACTAMS, MACROCYCLIC; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PHOSPHORYLCHOLINE; QUINONES; TUMOR CELLS, CULTURED;

EID: 0037163668     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600558     Document Type: Article

References (38)

1. Aboagye EO, Bhujwalla ZM (1999) Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 59: 80-84
2. An WG, Schnur RC, Neckers L, Blagosklonny MV (1997) Depletion of p185erbB2, Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity. Cancer Chemother Pharmacol 40: 60-64
3. Benchekroun MN, Schneider E, Safa AR, Townsend AJ, Sinha BK (1994) Mechanisms of resistance to ansamycin antibiotics in human breast cancer cell lines. Mol Pharmacol 46: 677-684
4. Clarke PA, Hostein I, Banerji U, Stefano FD, Maloney A, Walton M et al (2000) Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-Allylamino,-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene 19: 4125-4133
5. Cuadrado A, Carnero A, Dolfi F, Jimenez B, Lacal JC (1993) Phosphorylcholine: a novd second messenger essential for mitogenic activity of growth factors. Oncogene 8: 2959-2968
6. Cullis PR, Hope MJ (1991) Physical properties and functional roles of lipids in membranes. In Biochemistry of lipids, lipoproteins and membranes, Vance DE, Vance J (eds) pp 1-41. Amsterdam: Elsevier Science Publishers
7. Daum G, Eisenmann-Tappe I, Fries HW, Troppmair J (1994) The ins and outs of Raf kinases. Trends Biochem Sci 19: 474-480
8. Egorin MJ, Rosen DM, Wolff JH, Callery PS, Musser SM, Eiseman JL (1998) Metabolism of 17-(Allylamino)-17-demethoxygeldanamycin (NSC 330507) by Murine and Human Hepatic Preparations. Cancer Res 58: 2385-2396
9. Exton JH (1994) Phosphatidylcholine breakdown and signal transduction. Biochim Biophys Acta 1212: 26-42
10. Favata MF, Horiuchi KY, Manos EJ, Daulero AJ, Strapley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, Copeland RA, Magolda RL, Scherle PA, Trzaskos JM (1998) Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273: 18623-18632
11. Garrett MD, Workman P (1999) Discovering novel chemotherapeutic drugs for the third millennium. Eur J Cancer 35: 2010-2030
12. Gelmon KA, Eisenhauer EA, Harris LA, Ratain MJ, Workman P (1999) Anticancer agents targeting signaling molecules and cancer cell environment: Challenges for drug development. J Natl Cancer Inst 91: 1281-1287
13. Gibbs JB (2000) Anticancer drug targets: growth factors and growth factor signaling. J Clin Invest 105: 9-13
14. Grenert JP, Sullivan WP, Fadden P, Haystead TAJ, Clark J, Minnaugh E, Krutzsch H, Ochel HJ, Schulte TW, Sausville E, Neckers LM, Toft DO (1997) The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J Biol Chem 272: 23843-23850
15. 11C]choline. J Nucl Med 38: 842-847
16. Hara T, Kosaka N, Kishi H (1998) PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 39: 990-995
17. Hernandez-Alcoceba R, Saniger L, Campos J, Nunez MC, Khaless F, Gallo MA, Espinosa A, Lacal JC (1997) Choline kinase inhibitors as a novel approach for antiproliferative drug design. Oncogene 15: 2289-2301
18. Hostein I, Robertson D, DiStefano F, Workman P, Clark PA (2001) Inhibition of signal transduction by the Hsp90 inhibitor 17-Allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 61: 4003-4009
19. Hudes G (1999) Signaling inhibitors in the clinic: New agents and challenges. J Clin Oncol 17: 1093-1094
20. Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P (1999) DT-Diaphorase expression and tumor cell sensitivity to 17-Allylamino,-17-demethoxygeldanamycin, an inhibitor of Heat Shock Protein 90. Biochem Pharmacol 57: 281-289
21. Kim K-H, Carman GM (1999) Phosphorylation and regulation of choline kinase from Saccharomyces cerevisiae by protein kinase A. J Biol Chem 374: 9531-9538
22. cbl Phosphorylation in anti CD-3-stimulated T-lymphyoblasts. J Natl Cancer Inst 91: 1940-1949
23. Matter WF, Hui KY, Brown RF (1994) A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 267: 5241-5248
24. Mayer MP, Bukau B (1999) Molecular chaperones: The busy life of Hsp90. Curr Biol 9: R322-R325
25. Meijer L, Borgne A, Mulner O, Chong JP, Blow JJ, Inagaki N, Inagaki M, Delcros JG, Moulinoux JP (1997) Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 243: 527-536
26. Muise-Hemericks RC, Grimes HL, Bellacosa A, Malstrom SE, Tsichlis PN, Rosen N (1998) Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem 273: 29864-29872
27. Negendank W (1992) Studies of human tumors by MRS: a review. NMR Biomed 5: 303-324
28. O'Dwyer PJ, Stevenson JP, Gallagher M, Cassella A, Vasilevskaya I, Monia BP, Holmlund J, Dorr FA, Yao KS (1999) c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69346A). Clin Cancer Res 5: 3977-3982
29. Pelech SL, Vance DE (1989) Signal transduction via phosphatidylcholine cycles. Trends Biochem Sci 14: 28-30
30. Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW, Pearl LH (1997) Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 90: 65-75
31. Ratnam S, Kent C (1995) Early increase in choline kinase activity upon induction of the H-ras oncogene in mouse fibroblast cell lines. Arch Biochem Biophys 323: 313-322
32. Rudolph B, Saffrich R, Zwicker J, Henglein B, Muller R, Ansorge W, Eilers M (1996) Activation of cyclin-dependent kinases by Myc mediates induction of cyclin A, but not apoptosis. EMBO J 15: 3065-3076
33. Schulte TW, Blagosklonny MV, Romanova L, Mushinski JF, Monia BP, Johnston JF, Nguyen P, Trepel J, Neckers LM (1996) Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway. Mol Cell Biol 16: 5839-5845
34. Schulte TW, An WG, Neckers LM (1997) Geldanamycin-induced destabilization of Raf-1 involves the proteasome. Biochem Biophys Res Comm 239: 655-659
35. Smith TAD, Eccles S, Ormerod MG, Tombs AJ, Titley JC, Leach MO (1991) The phosphocholine and glycerophosphocholine content of oestrogen-sensitive rat mammary tumor correlates strongly with growth rate. Br J Cancer 64: 821-826
36. Spector T (1978) Refinement of the Coomassie blue method of protein quantitation. A simple and linear spectrophotometric assay for 0.5 to 50 mg of protein. Anal Biochem 86: 142-148
37. Thomas JE, Venugopalan M, Galvin R, Wang Y, Bokoch GM, Vlahos CJ (1997) Inhibition of MG-63 cell proliferation and PDGF-stimulated cellular processes by inhibitors of phosphatidylinositol 3-kinase. J Cell Biochem 64: 182-195
38. Zeisel SH (1981) Dietary choline: biochemistry, physiology, and pharmacology. Ann Rev Nutr 1: 95-121